Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-associated gastric ulcers in patients at continued risk and who require continuous NSAID treatment.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. A second 8-week course may be considered for patients who have not healed.
* **Maintenance of Healing:** 40 mg orally once daily.
* **NSAID-associated Gastric Ulcers:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally twice daily, but may be increased to 80 mg orally twice daily based on clinical response. Doses greater than 80 mg daily should be divided and administered every 12 hours. Maximum daily dose is 160 mg.
## Pediatric Dosing
* **Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years and older):**
* **Healing erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Symptomatic GERD (without esophagitis):** 20 mg orally once daily for up to 8 weeks.
* **Note:** Dosing in pediatric patients less than 5 years of age is not well established and requires careful consideration of risk/benefit.
## Dose Adjustments
No dose adjustment is necessary for patients with hepatic impairment or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use may be associated with increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH:** PPIs can decrease the absorption of drugs that require gastric acidity for absorption (e.g., ketoconazole, itraconazole, atazanavir, nelfinavir, iron salts, digoxin).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. It may affect the metabolism of drugs primarily metabolized by this enzyme (e.g., clopidogrel, voriconazole).
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile* infection.
* Monitor magnesium levels, particularly in patients on long-term therapy or taking concomitant medications that can cause hypomagnesemia (e.g., diuretics).
* Monitor for signs of bone fracture.
* Monitor for vitamin B12 deficiency in patients with prolonged treatment duration.
## Clinical Pearls
* Administer pantoprazole oral suspension and delayed-release tablets 30 minutes before a meal.
* The delayed-release tablets should be swallowed whole and not chewed or crushed.
* For patients unable to swallow tablets, the pantoprazole oral suspension can be administered.
* Consider the risks and benefits of long-term PPI use, especially for indications other than erosive esophagitis healing and maintenance.
***
**Disclaimer:** This information is intended for educational purposes and does not substitute for professional medical advice. Always verify the most current prescribing information with the official product monograph or other reliable sources before making clinical decisions.
